DJI136

DJI136 is a CAR-T cell therapy developed by Novartis Pharmaceuticals. Its target is DLL3 (the sponsor names DLL3). The sponsor states: DLL3-targeted chimeric antigen receptor (CAR) T-cell therapy administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07564401, plans to enrol 80 participants with primary completion expected 2031-03-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.